Continuous Infusion Versus Intermittent Bolus Injection of Rocuronium

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-23

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research is to find out whether continuous infusion of rocuronium requires more or less amount of rocuronium, per kilogram and per hour, than bolus administered rocuronium during noncardiac surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Simultaneous Injection of Propofol and Rocuronium in Inducing General Anesthesia

NCT03270696

Anesthesia; Functional

COMPLETED NA

Study of Rocuronium Onset Time According to Remifentanil Infusion

NCT01030510

Anesthesia

COMPLETED NA

Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane

NCT02711917

Neuromuscular Monitoring

COMPLETED NA

Intubation Time With Low Dose Rocuronium

NCT01464489

Intubation; Difficult

COMPLETED NA

Anesthesia Induction With Intravenous Bolus or Continuous Infusion of Remimazolam

NCT05423080

Adult Anesthesia, General

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

comparing the total dose of rocuronium between continuous infusion and intermittent injection

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Relaxation Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous infusion

The group of participants who are designated to receive continuously infused rocuronium.

Group Type EXPERIMENTAL

Rocuronium Bromide

Intervention Type DRUG

Continuously infuse, or bolus administer rocuronium.

Bolus administration

The group of participants who are designated to receive bolus administered rocuronium.

Group Type ACTIVE_COMPARATOR

Rocuronium Bromide

Intervention Type DRUG

Continuously infuse, or bolus administer rocuronium.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rocuronium Bromide

Continuously infuse, or bolus administer rocuronium.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric patients aged between 2 and 12, undergoing elective noncardiac surgery which requires general anesthesia but does not require intense block, and estimated time of surgery is between 2 and 5 hours

Exclusion Criteria

* ASA class 3-6
* BMI \>= 30
* Previous history of hepatic failure, renal failure or neuromuscular disease
* Patients taking medicine which interacts with rocuronium bromide, before or during surgery: aminoglycosides, lincosamides, acylamino-penicillin antibiotics, tetracyclines, metronidazole (high dose), diuretics, MAO inhibitors, calcium channel blockers, corticosteroids, phenytoin, carbamazepine, or norepinephrine
* Previous history of allergic reaction (including anaphylactic reaction) and/or malignant hyperthermia during general anesthesia
* Patients taking medicines which contains magnesium

Minimum Eligible Age

2 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No